U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07435415) titled 'Local Injection Methylene Blue Combined With Radiation in HNSCC Patients' on Nov. 22, 2025.
Brief Summary: The goal of this clinical trial is to investigate the effectiveness of Methylene Blue (MB) as a radiosensitizer in treating head and neck squamous cell carcinoma (HNSCC) that has recurred locally and is resistant to radiation therapy. It will also assess the safety of Methylene Blue. The main questions it aims to answer are:
Does Methylene Blue improve the outcomes for patients with recurrent HNSCC receiving radiation therapy? What side effects do participants experience while receiving Methylene Blue?
Participants will:
Rec...